Autres langues NetraMark Holdings Inc. OTC Markets

Actions

AINMF

CA64119M1059

Marché Fermé - OTC Markets Autres places de cotation 20:05:14 11/07/2024			Varia. 5j.	Varia. 1 janv.
0,205 ^USD	-3,21 %		-6,61 %	-22,17 %

10/06	NetraMark Holdings Inc. annonce un accord de collaboration avec le National Institute of Mental Health pour analyser les données des essais cliniques sur l'utilisation de la kétamine dans les troubles mentaux	CI
14/05	NetraMark Holdings Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

NetraMark Holdings Inc. Announces Collaboration Agreement with National Institute of Mental Health to Analyze Clinical Trial Data on the Use of Ketamine in Mental Disorders	10/06
NETRAMARK ANNOUNCES COLLABORATION AGREEMENT WITH NIMH TO ANALYZE CLINICAL TRIAL DATA ON THE USE OF KETAMINE IN PSYCHIATRIC DISORDERS	10/06
257,550 Common Share of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2024.	09/06
30,000 Options of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2024.	09/06
NETRAMARK TO INTRODUCE THE TREATMENT ATTITUDE PROFILE (TAP™) SCALE FOR PLACEBO RESPONSE PERSONA DISCOVERY USING ITS NETRA AI TECHNOLOGY AT THE 2024 ASCP ANNUAL MEETING	28/05
NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	14/05
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS	10/04
Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	10/04
NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS	05/04
PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD	04/04
NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	04/04
NETRAMARK PROVIDES BUSINESS UPDATE AND HIGHLIGHTS PROGRESS	02/04
NETRAMARK SIGNS CONTRACT WITH PHARMACEUTICAL COMPANY TO DELIVER CLINICAL TRIAL INSIGHTS REGARDING EFFICACY AND PLACEBO RESPONSE	12/03
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response	12/03
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights	11/03
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES PARKINSON'S DISEASE SUBTYPES LINKED BY MITOCHONDRIAL, MICROBIOME AND IMMUNE SIGNALING	11/03
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution	11/03
NETRAMARK TO PRESENT NEW DATA HIGHLIGHTING THE UTILITY OF IT'S AI-BASED CLINICAL SOLUTION IN IDENTIFYING PARKINSON'S DISEASE ASSOCIATED BIOMARKERS AT AD/PD™ 2024	29/02
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial	27/02
NETRAMARK SIGNS FOURTH CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues NetraMark Holdings Inc. OTC Markets

Actions

AINMF

CA64119M1059

Autres langues

Filtres